In Vivo Therapeutics Core Services
I. Pharmacological Investigations:
In vitro toxicity testing
- Utilize primary human hematopoietic cells and clonogenic progenitor assays to test effects of new compounds on normal cellular function
In Vivo Dose Range Finding
- Coordinate pharmacokinetic studies with the Clinical Pharmacology Analytical Core (CPAC) in the School of Medicine
- Develop a rational dosing regimen for testing efficacy of therapy
- Assess potential in vivo toxicity of new compounds and/or combination therapies
- Complete blood count (20 parameters)
- Blood chemistry analysis to monitor organ/tissue toxicity-panels in development
- Coordinate end-point analysis (necropsy and histology) with the Investigative Toxicology/Pathology Core (ITPC) in the Center for Environmental Health
In Vivo Tumor Growth Kinetics
- Facilitate development of novel xenograft models
- Document tumor progression of previously untested tumors prior to drug efficacy study in immunodeficient mice.
Tumor cell lines currently available: U87-MG (glioblastoma), SF767 (glioblastoma), SKOV-3X (ovarian), A549 (lung), ovarian (SKOV3X) and MCF-7 (breast)
In Vivo Drug Efficacy/Tumor Xenograft Model
- Establish tumors and administer drug regimen
- Document tumor progression in vehicle- and drug-treated mice
- Coordinate end-point analysis (necropsy and histology) with the Investigative Toxicology/Pathology Core (ITPC) in the Center for Environmental Health
II. Cellular Therapies:
- Radiation of mice prior to transplantation
- Intravenous injection of hematopoietic stem cells into mice
- Provide investigator blood samples from transplanted mice